Hugo M. Horlings

Citado por

	Total	Desde 2020
Citas	27937	13362
Índice h	59	44
Índice i10	115	104

2800

1400

700

2100

200820092010201120122013201420152016201720182019202020212022202320242025166 409 621 778 993 1207 1432 1565 1680 1713 1804 1916 2508 2798 2705 2532 2441 368

Acceso público

Ver todo

94 artículos

9 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Sabine LinnProfessor of Translational Oncology - Utrecht University; Group leader NKI AmsterdamDirección de correo verificada de nki.nl
Rene BernardsNetherlands Cancer InstituteDirección de correo verificada de nki.nl
fabien reyalInstitut Curie. Department of SurgeryDirección de correo verificada de curie.fr
Jelle WesselingGroup Leader, Netherlands Cancer InstituteDirección de correo verificada de nki.nl
David HuntsmanBC Cancer AgencyDirección de correo verificada de bccancer.bc.ca
Howard Y. ChangChief Scientific Officer, AmgenDirección de correo verificada de stanford.edu
Saraswati SukumarProfessor of OncologyDirección de correo verificada de jhmi.edu
Anita LangerødResearcher, Oslo University HospitalDirección de correo verificada de rr-research.no
Ali BashashatiUniversity of British Columbia/Vancouver Coastal Health Research InstituteDirección de correo verificada de bccrc.ca
Sohrab ShahMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Gordon MillsOregon Health & Science UniversityDirección de correo verificada de ohsu.edu
Pedram ArganiProfessor of Pathology and Oncology, Johns Hopkins UniversityDirección de correo verificada de jhmi.edu
Rachael NatrajanThe Institute of Cancer ResearchDirección de correo verificada de icr.ac.uk
Michael S. AnglesioAssistant Professor, Department of Obstetrics & Gynaecology, University of British ColumbiaDirección de correo verificada de ubc.ca
Petra M NederlofNetherlands Cancer Institute NKIDirección de correo verificada de nki.nl
Manolis KellisProfessor of Computer Science, MIT and Broad InstituteDirección de correo verificada de mit.edu
Michael F. Linindependent (mlin.net LLC)Dirección de correo verificada de mlin.net
Jos JonkersProfessor at Leiden University and group leader at Netherlands Cancer Institute, Oncode InstituteDirección de correo verificada de nki.nl
Oscar krijgsmanPrinciple Bioinformatician, Neogene TherapeuticsDirección de correo verificada de neogene.com
Joe GrayBiomedical Engineering, Oregon Health and Science UniversityDirección de correo verificada de ohsu.edu

Seguir

Hugo M. Horlings

MD PhD, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Dirección de correo verificada de nki.nl - Página principal

Molecular pathology therapy resistance oncogenic pathways breast cancer ovarian cancer


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis RA Gupta, N Shah, KC Wang, J Kim, HM Horlings, DJ Wong, MC Tsai, ... nature 464 (7291), 1071-1076, 2010	5930	2010
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer K Berns, HM Horlings, BT Hennessy, M Madiredjo, EM Hijmans, K Beelen, ... Cancer cell 12 (4), 395-402, 2007	1932	2007
AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017	1482	2017
Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters T Hung, Y Wang, MF Lin, AK Koegel, Y Kotake, GD Grant, HM Horlings, ... Nature genetics 43 (7), 621-629, 2011	1392	2011
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer K Stemke-Hale, AM Gonzalez-Angulo, A Lluch, RM Neve, WL Kuo, ... Cancer research 68 (15), 6084-6091, 2008	1228	2008
Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma H Li, AM van der Leun, I Yofe, Y Lubling, D Gelbard-Solodkin, ... Cell 176 (4), 775-789. e18, 2019	978	2019
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas B Kreike, M van Kouwenhove, H Horlings, B Weigelt, H Peterse, ... Breast Cancer Research 9, 1-14, 2007	868	2007
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck M Persson, Y Andrén, J Mark, HM Horlings, F Persson, G Stenman Proceedings of the National Academy of Sciences 106 (44), 18740-18744, 2009	863	2009
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928, 2019	815	2019
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017	800	2017
Refinement of breast cancer classification by molecular characterization of histological special types B Weigelt, HM Horlings, B Kreike, MM Hayes, M Hauptmann, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2008	736	2008
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017	700	2017
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators R Mezzadra, C Sun, LT Jae, R Gomez-Eerland, E De Vries, W Wu, ... Nature 549 (7670), 106-110, 2017	640	2017
Cancer-associated mutations in endometriosis without cancer MS Anglesio, N Papadopoulos, A Ayhan, TM Nazeran, M Noë, ... New England Journal of Medicine 376 (19), 1835-1848, 2017	635	2017
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, ... Oncogene 29 (14), 2013-2023, 2010	477	2010
MicroRNA sequence and expression analysis in breast tumors by deep sequencing TA Farazi, HM Horlings, JJ Ten Hoeve, A Mihailovic, H Halfwerk, ... Cancer research 71 (13), 4443-4453, 2011	436	2011
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis LCW Vredeveld, PA Possik, MA Smit, K Meissl, C Michaloglou, ... Genes & development 26 (10), 1055-1069, 2012	329	2012
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe JWR Hovius, B de Wever, M Sohne, MC Brouwer, J Coumou, ... The Lancet 382 (9892), 658, 2013	319	2013
An acquired vulnerability of drug-resistant melanoma with therapeutic potential L Wang, RL de Oliveira, S Huijberts, E Bosdriesz, N Pencheva, D Brunen, ... Cell 173 (6), 1413-1425. e14, 2018	305	2018
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes YK Wang, A Bashashati, MS Anglesio, DR Cochrane, DS Grewal, G Ha, ... Nature genetics 49 (6), 856-865, 2017	278	2017

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores